Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL2-BCG: Bendamustine, Obinutuzumab, and Idelalisib in CLL
NCT02445131Phase 2Completed
- Sponsor
- German CLL Study Group
- Start
- May 2015
- Primary completion
- Mar 2022
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab, idelalisib in chronic lymphocytic leukemia (CLL), sponsored by German CLL Study Group. Started May 2015; status: completed.
02
Drugs
obinutuzumabidelalisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02445131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02445131.